MARKET DYNAMICS Driving Factor Rising prevalence of diabetes and obesity The Liraglutide and Semaglutide Market Growth is primarily driven by the increasing global burden of diabetes and obesity, with over 537 million adults affected by diabetes worldwide and obesity prevalence exceeding 39% among adults
By improving the bodys ability to use fat as a fuel source, ALCAR enhances endurance, reduces reliance on carbohydrates, and supports muscle recovery and overall performance
Announcing our new GLP-1 prescribing offering: where clinical excellence meets behavior change
Noom uses GLP-1s as part of a program to help kickstart a lasting identity shift
For international shipping, it may take 7-14 business days depending on the destination
Many patients were prescribed both GLP-1 agonists and metformin, but the GLP-1 agonists did not show a risk reduction when compared to metformin alone